REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients "REGENESIS"


Phase 2 Results N/A

Summary of Purpose

Primary objective: To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a placebo control. Secondary objective: To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke patients.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 10 August 2009.

1 Mar 2008 18 Apr 2008 1 Oct 2008 1 Jan 2009 1 Aug 2009 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment


  • Karla Ryckborst Department of Clinical Neurosciences, Univeristy of Calgary Calgary, Alberta, Canada, T2N 2T9 Phone: 403-944-2863